Stockreport

Rallybio commences Phase II trial of RLYB212 for FNAIT in pregnant women [Yahoo! Finance]

Rallybio Corporation  (RLYB) 
PDF fatal condition that causes severe bleeding in foetuses and newborns. The open-label trial will assess the safety and dosage of RLYB212 in pregnant women at higher risk [Read more]